Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040 | Chief Business Officer | July 21, 2020 | July 21, 2020 |
| Candel Therapeutics, Inc.CADL · Entity 4969 | Chief Business Officer | July 29, 2021 | August 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALX ONCOLOGY HOLDINGS INC
Report date July 21, 2020 · Filed July 21, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 11,254 |
Reported balance
After 2020-07-21 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-07-21 · Conversion · Acquired 10,529 · Balance 11,254 F1: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F2: Includes 725 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020. F3: The shares are held of record by the reporting person's spouse. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-07-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-07-21 · Conversion · Disposed 10,529 · Balance 0 F1: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F3: The shares are held of record by the reporting person's spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.
F2: Includes 725 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020.
F3: The shares are held of record by the reporting person's spouse.
Candel Therapeutics, Inc.
Report date July 29, 2021 · Filed August 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,000 |
Reported balance
After 2021-07-29 transaction · row 1
1 source rowRow 1 · 2021-07-29 · Purchase · Acquired 6,000 · Balance 6,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2021 Filed Aug 2, 2021 20:02 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | PurchaseCommon Stock | 6,000 | $8.00 | $48,000.00 |
DisclosureSEC source: 0000899243-21-031086 · doc4.xml · nonDerivative · entry 1 Caffo Nathan · CIK 0001816992 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Read SEC document |
| July 21, 2020 Filed Jul 21, 2020 19:56 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries B Convertible Preferred Stock · Derivative | 10,529 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019906 · doc4.xml · derivative · entry 2 Caffo Nathan · CIK 0001816992 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 10,529 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F1 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F1 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F1 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F3 · ownership.nature: The shares are held of record by the reporting person's spouse. Read SEC document |
| July 21, 2020 Filed Jul 21, 2020 19:56 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionCommon Stock | 10,529 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019906 · doc4.xml · nonDerivative · entry 1 Caffo Nathan · CIK 0001816992 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 11,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F2 · balance_after: Includes 725 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020. F3 · ownership.nature: The shares are held of record by the reporting person's spouse. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 19:01 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 22,794 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019573 · doc4.xml · derivative · entry 1 Caffo Nathan · CIK 0001816992 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,794 Underlying: Common Stock · 22,794 shares Expires 2030-07-16 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on August 16, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.